Table 1.
Treatment | Maximal changes in MAP (mm Hg) | Maximal changes in HR (bpm) |
---|---|---|
Saline | 3.5 ± 0.3 | 5.7 ± 1.0 |
L-NAME (2 nmol) | 3.9 ± 0.9 | 7.6 ± 3.6 |
L-NAME (20 nmol) | 3.2 ± 0.9 | 9.8 ± 4.1 |
7-NiNa (0.05 pmol) | 3.0 ± 0.8 | 8.6 ± 3.3 |
7-NiNa (0.1 pmol) | 3.0 ± 0.6 | 8.2 ± 3.8 |
L-NIO (100 pmol) | 3.2 ± 0.2 | 5.9 ± 2.1 |
L-NIO (200 pmol) | 2.9 ± 1.0 | 8.5 ± 3.8 |
SMIT (250 pmol) | 2.8 ± 0.5 | 7.4 ± 4.6 |
SMIT (500 pmol) | 2.6 ± 0.5 | 9.1 ± 4.8 |
BIC (100 pmol) | 2.4 ± 0.5 | 6.3 ± 5.4 |
BIC (200 pmol) | 2.9 ± 0.6 | 9.0 ± 4.9 |
Saline or different blockers were microinjected into the PVN, and the maximal changes in mean arterial pressure (MAP) and heart rate (HR) between 10 and 15 min after the injections were recorded. For each group, N was at least 6. There were no significant differences between the changes in MAP and HR after saline injection and those after the injections of the blockers.